RT Journal Article
SR Electronic
T1 Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.12.21249713
DO 10.1101/2021.01.12.21249713
A1 Naushin, Salwa
A1 Sardana, Viren
A1 Ujjainiya, Rajat
A1 Bhatheja, Nitin
A1 Kutum, Rintu
A1 Bhaskar, Akash Kumar
A1 Pradhan, Shalini
A1 Prakash, Satyartha
A1 Khan, Raju
A1 Rawat, Birendra Singh
A1 Tallapaka, Karthik Bharadwaj
A1 Anumalla, Mahesh
A1 Chandak, Giriraj Ratan
A1 Lahiri, Amit
A1 Kar, Susanta
A1 Mulay, Shrikant Ramesh
A1 Mugale, Madhav Nilakanth
A1 Srivastava, Mrigank
A1 Khan, Shaziya
A1 Srivastava, Anjali
A1 Tomar, Bhawna
A1 Veerapandian, Murugan
A1 Venkatachalam, Ganesh
A1 Vijayakumar, Selvamani Raja
A1 Agarwal, Ajay
A1 Gupta, Dinesh
A1 Halami, Prakash M
A1 Peddha, Muthukumar Serva
A1 Sundaram, Gopinath M
A1 Veeranna, Ravindra P
A1 Pal, Anirban
A1 Agarwal, Vinay Kumar
A1 Maurya, Anil Ku
A1 Kumar Singh, Ran Vijay
A1 Raman, Ashok Kumar
A1 Anandasadagopan, Suresh Kumar
A1 Karuppanan, Parimala
A1 Venkatesan, Subramanian
A1 Sardana, Harish Kumar
A1 Kothari, Anamika
A1 Jain, Rishabh
A1 Thakur, Anupma
A1 Parihar, Devendra Singh
A1 Saifi, Anas
A1 Kaur, Jasleen
A1 Kumar, Virendra
A1 Mishra, Avinash
A1 Gogeri, Iranna
A1 Rayasam, Geethavani
A1 Singh, Praveen
A1 Chakraborty, Rahul
A1 Chaturvedi, Gaura
A1 Karunakar, Pinreddy
A1 Yadav, Rohit
A1 Singhmar, Sunanda
A1 Singh, Dayanidhi
A1 Sarkar, Sharmistha
A1 Bhattacharya, Purbasha
A1 Acharya, Sundaram
A1 Singh, Vandana
A1 Verma, Shweta
A1 Soni, Drishti
A1 Seth, Surabhi
A1 Vashisht, Shakshi
A1 Thakran, Sarita
A1 Fatima, Firdaus
A1 Singh, Akash Pratap
A1 Sharma, Akanksha
A1 Sharma, Babita
A1 Subramanian, Manikandan
A1 Padwad, Yogendra
A1 Hallan, Vipin
A1 Patial, Vikram
A1 Singh, Damanpreet
A1 Tirpude, Narendra Vijay
A1 Chakrabarti, Partha
A1 Maity, Sujay Krishna
A1 Ganguly, Dipyaman
A1 Sarkar, Jit
A1 Ramakrishna, Sistla
A1 Kumar, Balthu Narender
A1 Kumar, A Kiran
A1 Gandhi, Sumit G.
A1 Jamwal, Piyush Singh
A1 Chouhan, Rekha
A1 Jamwal, Vijay Lakshmi
A1 Kapoor, Nitika
A1 Ghosh, Debashish
A1 Thakkar, Ghanshyam
A1 Subudhi, Umakanta
A1 Sen, Pradip
A1 Chaudhury, Saumya Ray
A1 Kumar, Rashmi
A1 Gupta, Pawan
A1 Tuli, Amit
A1 Sharma, Deepak
A1 Ringe, Rajesh P.
A1 D, Amarnarayan
A1 Kulkarni, Mahesh
A1 Shanmugam, Dhanasekaran
A1 Dharne, Mahesh S
A1 Dastager, Syed G.
A1 Joshi, Rakesh
A1 Patil, Amita P.
A1 Mahajan, Sachin N.
A1 Khan, Abu Junaid
A1 Wagh, Vasudev
A1 Yadav, Rakeshkumar
A1 Khilari, Ajinkya
A1 Bhadange, Mayuri
A1 Chaurasiya, Arvindkumar H.
A1 Kulsange, Shabda E
A1 Khairnar, Krishna
A1 Paranjape, Shilpa
A1 Kalita, Jatin
A1 Sastry, G. Narahari
A1 Phukan, Tridip
A1 Manna, Prasenjit
A1 Romi, Wahengbam
A1 Bharali, Pankaj
A1 Ozah, Dibyajyoti
A1 Sahu, Ravi Kumar
A1 Babu, Elapavalooru V.S.S.K.
A1 Sukumaran, Rajeev
A1 Nair, Aiswarya R
A1 Kooloth-Valappil, Prajeesh
A1 Puthiyamadam, Anoop
A1 Velayudhanpillai, Adarsh
A1 Chodankar, Kalpana
A1 Damare, Samir
A1 Madhavi, Yennapu
A1 Aggarwal, Ved Varun
A1 Dahiya, Sumit
A1 Agrawal, Anurag
A1 Dash, Debasis
A1 Sengupta, Shantanu
YR 2021
UL http://medrxiv.org/content/early/2021/01/16/2021.01.12.21249713.abstract
AB Background India has been amongst the most affected nations during the SARS-CoV2 pandemic, with sparse data on country-wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS-CoV2 sero-positivity rate as a marker of infection and evaluate temporal persistence of antibodies with neutralization capability and to infer possible risk factors for infection.Methods Council of Scientific and Industrial Research, India (CSIR) with its more than 40 laboratories and centers in urban and semi-urban settings spread across the country piloted the pan country surveillance. 10427 adult individuals working in CSIR laboratories and their family members based on voluntary participation were assessed for antibody presence and stability was analyzed over 6 months utilizing qualitative Elecsys SARS CoV2 specific antibody kit and GENScript cPass SARS-CoV2 Neutralization Antibody Detection Kit. Along with demographic information, possible risk factors were evaluated through self to be filled online forms with data acquired on blood group type, occupation type, addiction and habits including smoking and alcohol, diet preferences, medical history and transport type utilized. Symptom history and information on possible contact and compliance with COVID 19 universal precautions was also obtained.Findings 1058 individuals (10·14%) had antibodies against SARS-CoV2. A follow-up on 346 sero-positive individuals after three months revealed stable to higher antibody levels against SARS-CoV2 but declining plasma activity for neutralizing SARS-CoV2 receptor binding domain and ACE2 interaction. A repeat sampling of 35 individuals, at six months, revealed declining antibody levels while the neutralizing activity remained stable compared to three months. Majority of sero-positive individuals (75%) did not recall even one of nine symptoms since March 2020. Fever was the most common symptom with one-fourth reporting loss of taste or smell. Significantly associated risks for sero-positivity (Odds Ratio, 95% CI, p value) were observed with usage of public transport (1·79, 1·43 – 2·24, 2·81561E-06), occupational responsibilities such as security, housekeeping personnel etc. (2·23, 1·92 – 2·59, 6·43969E-26), non-smokers (1·52, 1·16 – 1·99, 0·02) and non-vegetarianism (1·67, 1·41 – 1·99, 3·03821E-08). An iterative regression analysis was confirmatory and led to only modest changes to estimates. Predilections for sero-positivity was noted with specific ABO blood groups -O was associated with a lower risk.Interpretation In a first-of-its-kind study from India, we report the sero-positivity in a country-wide cohort and identify variable susceptible associations for contacting infection. Serology and Neutralizing Antibody response provides much-sought-for general insights on the immune response to the virus among Indians and will be an important resource for designing vaccination strategies.Funding Council of Scientific and Industrial Research, India (CSIR)Competing Interest StatementThe authors have declared no competing interest.Funding StatementCouncil of Scientific and Industrial Research, India (CSIR) The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CSIR IGIB: Institutional Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified categorized data of the participants can be provided on request basis after approval of ethics committee of the institute/organisation to which the requesting person belongs, stating the potential need and usage and signing of an agreement with the corresponding authors on behalf of CSIR IGIB. The request could be made to the corresponding authors after 90 days of publication.